Product Pipeline

CSL040 Complement Activation Inhibitor

A recombinant glycoprotein which inhibits the classical, lectin and alternative Complement pathways for the potential treatment of Transplant-related ischemia-reperfusion injury (IRI) [eg. primary graft dysfunction (PGD) in lung and delayed graft function (DGF) in kidney]

CSL400 sa-mRNA Influenza Vaccine

For protection against seasonal influenza viruses using self-amplifying mRNA platform

CSL404 Cell-based Pandemic Influenza (H5N8) Vaccine^#

For protection against influenza A (H5N8) virus strain

CSL405 Cell-based Pandemic Influenza (H2N3) Vaccine^#

For protection against Pandemic Influenza A (H2N3)

CSL406 sa-mRNA Pandemic Influenza (H5N1) Vaccine

For protection against Pandemic Influenza A (H5N1)

CSL787 Nebulised Ig

Human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease such as Non-Cystic Fibrosis Bronchiectasis (NCFB).

Anumigilimab Anti-G-CSFR mAb (SCD prophylaxis)

An anti-G-CSFR recombinant monoclonal antibody for prophylactic use in Sickle Cell Disease to reduce the incidence of vaso-occlusive crises

Hemopexin (VOC in SCD)

Plasma-derived hemopexin for potential treatment of acute Vascular Occlusive Crisis (VOC) in Sickle Cell Disease (SCD) patients.

Vamifeport Ferroportin Inhibitor (HH)

Oral Ferroportin Inhibitor (small molecule) for treatment of iron overload in hereditary hemochromatosis

CSL301 Anti-α2AP mAb (sPE)*

Anti-α2-antiplasmin monoclonal antibody, which is being developed to dissolve thrombi that cause serious conditions such as submassive pulmonary embolism (sPE) and acute ischemic stroke (AIS).

HIZENTRA^® (SCIg) 20% Liquid (CLL)

Subcutaneous 20% Immune Globulin (SCIg)(Plasma) to treat Secondary Immunodeficiency (SID) as a result of Chronic Lymphocytic Leukemia (CLL)

HIZENTRA^® (SCIg) 20% Liquid (PID Naïve)

Subcutaneous 20% Immune Globulin (SCIg)(Plasma) to treat Primary Immunodeficiency (PID) for patients without prior IVIg treatments

Horizon 2 Ig Yield

Using novel technologies to optimise processes for increased Ig yield

KCENTRA^® PCC (Surgical Bleeding)

Prothrombin complex concentrate (PCC) for the potential use in surgical settings with high risk of major bleeding.

RiaSTAP^® Fibrinogen Concentrate (AFD)

Lyophilised fibrinogen for treatment of Acquired Fibrinogen Disease (AFD)

Clazakizumab Anti-IL-6 mAb (ESKD)

Clazakizumab (an anti-IL6 antibody) for the prevention of cardiovascular morbidity and mortality in patients with end-stage kidney disease

CSL964 Alpha 1 Antitrypsin (Prevention of aGvHD)

Prevention of acute Graft-versus-Host Disease (aGvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).

CSL964 Alpha 1 Antitrypsin (Treatment of aGvHD)*

Treatment of steroid refractory, acute Graft-versus-Host Disease (aGvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).

HIZENTRA^® (SCIg) 20% Liquid

Subcutaneous 20% Immune Globulin (SCIg)(Plasma) to treat Primary Immunodeficiency (PID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Secondary Immunodeficiency (SID)

PRIVIGEN^® (IVIg) 10% Liquid

Intravenous 10% Immune Globulin (IVIg)(Plasma) for the treatment of Primary Immunodeficiency (PID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Secondary Immunodeficiency (SID), Chronic Immune Thrombocytopenia (ITP)

ZEMAIRA^®/RESPREEZA^® Alpha 1 Antitrypsin (AAT Deficiency)

Human Alpha 1 Antitrypsin (AAT) (Plasma) for chronic augmentation and maintenance therapy in adults with A1-PI deficiency and emphysema

AFSTYLA^® rFVIII (Hem A)

Recombinant factor VIII product for the treatment of adults and children with hemophilia A.

IDELVION^® rFIX-FP (Hem B)

Long-acting recombinant factor IX product for the treatment of hemophilia B.

HEMGENIX^® (Hem B)

Adeno-associated virus vector-based gene therapy indicated for treatment of adults with Hemophilia B (congenital Factor IX deficiency).

ANDEMBRY^® Anti-FXIIa mAb (HAE)

Subcutaneous humanised anti-factor XIIa monoclonal antibody for the treatment of Hereditary Angioedema (HAE).

FILSPARI^®(Sparsentan) Dual ET_A & AT₁ antagonist (IgAN)*

Oral, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist (DEARA) with high selectivity for the ET_AR and AT₁R for treatment of immunoglobulin A nephropathy (IgAN).

KORSUVA^®/KAPRUVIA^® KOR. agonist (CKD-aP)*

Difelikefalin - a kappa-opioid receptor (KOR) agonist for treatment of moderate-to-severe pruritus associated with CKD in adult patients on hemodialysis.

RAYALDEE^® Oral ext. release calcifediol (SHPT)*

Orally administered, prolonged-release formulation of calcifediol for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency or deficiency.

TAVNEOS^® Oral C5a receptor inhibitor (AAV)^*

Orally administered, highly potent and selective inhibitor of C5aR1 (complement C5a receptor 1) for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (ANCA)-associated vasculitis (AAV).

VELPHORO^® Sucroferric oxyhydroxide (Serum P control in CKD)

A non-calcium, iron-based phosphate binder used for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on hemodialysis or peritoneal dialysis.

VELTASSA^® Oral potassium binder (HK)

A non-absorbed, oral potassium binder for the treatment of hyperkalemia.

AUDENZ^®/CELLDEMIC^® Adjuvanted Cell-based Monovalent Influenza A (H5N1) Vaccine

For protection against Pandemic Influenza A (H5N1)

FLUAD^® Adjuvanted Egg-based Influenza Vaccine

Egg-based vaccine combined with CSL Seqirus' proprietary adjuvant, MF59^® (an additive that acts to strengthen the immune response to vaccination) for protection against influenza A (H5N1) - the 'bird-flu' strain.

FLUCELVAX^® Cell-based Influenza Vaccine

For protection against seasonal influenza viruses in adults and children 6 months of age and older.

FOCLIVIA^®/AFLUNOV^® Adjuvanted Egg-based Influenza A (H5N1) Vaccine

Pre-pandemic, egg-based vaccine combined with CSL Seqirus' proprietary adjuvant, MF59^® (an additive that acts to strengthen the immune response to vaccination), for protection against influenza A (H5N1) - the 'bird-flu' strain.

KOSTAIVE^® sa-mRNA Vaccine (COVID)*

Novel seasonal COVID-19 booster vaccine using self-amplifying platform offering higher efficacy and longer duration and breadth of protection at lower doses of mRNA.

CSL403 (aTIVc) Adjuvanted Cell-based Trivalent Influenza Vaccine

Trivalent Seasonal Influenza Vaccine (Adjuvanted; Cell-based). High dose vaccine offering protection against different influenza virus strains.